A comparative drug utilisation study of the treatment of diabetes in Malaysia and Australia

Australasian Medical Journal

Volumn 8, Issue 6, 2013, Pages 179-188

  Hasan, Syed S ^a   Clavarino, Alexandra M ^a   Mamun, Abdullah A ^a   Kairuz, Therese ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Australia; Diabetes; Drugs; Insulin; Malaysia; Metformin; Utilisation

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; AUSTRALIA; DIABETES MELLITUS; DRUG USE; DRUG UTILIZATION; HUMAN; MALAYSIA; PRESCRIPTION; PREVALENCE;

EID: 84934764249     PISSN: None     EISSN: 18361935     Source Type: Journal    
DOI: 10.4066/AMJ.2015.2330     Document Type: Article

References (39)

1. Gallwitz B. Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. Diabetes Care. 2009;32(2):S322–5.
2. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–57.
3. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.
4. United Nations, Population Division, World Population Prospects: The 2006 Revision. United Nations (Ed.). Geneva, 2007.
5. Letchuman GR, Wan Nazaimoon WM, et al. Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006. Med J Malaysia. 2010;65:173–9.
6. Zaini A. Where is Malaysia in the midst of the Asian epidemic of diabetes mellitus? Diabetes Res Clin Pract. 2000;50:23–8.
7. Wan Nazaimoon WM, Md Isa SH, Wan Mohamad WB, et al. Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion. Diabet Med. 2013;30(7):825–8.
8. Diabetes in Australia Updates [Internet]. [Accessed 2014 Jul 12]. Available from: http://www.diabetesaustralia.com.au/Understanding-Diabetes/Diabetes-in-Australia
9. Australian Bureau of Statistics: National Health Survey; Diabetes (1995), cat 4371.0.
10. Australian Bureau of Statistics: National Health Survey: Summary of Results, 2007–2008 (Reissue), cat, 4364.0.
11. Australian Bureau of Statistics: Australian Health Survey; Diabetes Mellitus, 2011–12, cat 4364.0.55.001.
12. Australia Health: Authoritative information and statistics to promote better health and wellbeing [Internet]. [Accessed 2013 Oct 08]. Available from: http://www.aihw.gov.au/publication-detail/?id=6442468376
13. Schneeweiss S, Avron J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–7.
14. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25(5):829–83.
15. National Diabetes Service Scheme, Diabetes Australia [Internet]. [Accessed 2014 Jan 21]. Available from: http://ndss.com/au/en/Australian-Diabetes-Map/Map/
16. Malaysian statistics on medicine use [Internet]; 2004 to 2008. [Accessed 2014 Jun 01]. Available from: http://www.pharmacy.gov.my/v2/en/documents/malaysian-statistics-medicines.html
17. Australian Government Department of Health and Ageing. Australian Statistics on Medicines [Internet]; 1997 to 2008. [Accessed 2014 Jun 01]. Available from: http://www.pbs.gov.au/info/browse/statistics
18. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2009.
19. Australian Government Department of Health and Ageing 2004. Australian Statistics on Medicines 2001–2002. Canberra: Australian Government Publishing Service.
20. Nordic Council on Medicines. Nordic Statistics on Medicines 1987–1989. NLN publication number 3, Uppsala, Sweden, 1990.
21. Australian Bureau of Statistics: Australian Demographic Statistics (2011), cat 3101.0.
22. Department of Statistics Malaysia: Malaysian Demographics Statistics [Internet]. [Accessed 2014 Jan 21]. Available from: http://www.statistics.gov.my/portal/index.php?option=com_content&id=1215&Itemid=89&lang=en
23. Institute for Public Health (IPH) 2011. National Health and Morbidity Survey 2011 (NHMS 2011). Vol. 2: Non-Communicable Diseases; 2011: 188 pages.
24. Mafauzy M, Hussein Z, Chan SP. The stauts of diabetes control in Malaysia: results of DiabCare 2008. Med J Malaysia. 2011;66(3):175–81.
25. International Diabetes Federation. Diabetes Atlas Third Edition. Brussels: IDF [Internet]. [Accessed 2013 Nov 10]. Available from: http://www.euphix.org/object_document/o4858n27165.html
26. Clinical Practice Guidelines Task Force. Clinical Practice Guidelines Management of Type 2 Diabetes Mellitus (3rd Edition). Ministry of Health Malaysia 2004.
27. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infaction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457–71.
28. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA. 2003;289(17):2265–9.
29. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: National clinical guideline for management in primary and secondary care (updated NICE guidelines-2008).
30. Macisaac RJ, Jerums G, Weekes AJ, et al. Patterns of glycaemic control in Australian primary care (NEFRON 8). Intern Med J. 2009;39:512–8.
31. Deed G, Barlow J, Kuo I. Early and tight glycaemic control: the key to managing type 2 diabetes. Aust Fam Physician. 2012; 41(9): 681-684.
32. Chiasson JL. Early insulin use in type 2 diabetes. Diabetes Care. 2009;32(2):S270–4.
33. International diabetes federation: clinical guidelines task force (2005). Global guideline for type 2 diabetes. [Accessed 2014 Jan 21]. Available from: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf
34. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemic with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
36. Lee YK, Ng CJ, Lee PY, et al. What are the barriers faced by patients using insulin? A qualitative study of Malaysian health care professionals’ views. Patient Prefer Adherence. 2013;7:103–9.
37. Hasan SS, Ahmed SI, Bukhari NI, et al. Use of complementary and alternative medicine among patients with chronic diseases at outpatient clinics. Complement Ther Clin Pract. 2009;15:152–7.
38. Hasan SS, Loon WCW, Ahmadi K, et al. Reasons, perceived efficacy and factors associated with complementary and alternative medicine use among Malaysian patients with diabetes mellitus. British Journal of Diabetes Vascular Disease. 2011;11(2):92–8.
39. Babar ZUD, Ibrahim MIM, Singh H, et al. Evaluating drug prices, availability, affordability, and price components: Implications for access to drugs in Malaysia. PLoS Med. 2007;4(3):466–75.